Strong Generics-led finish to 2023
22/02/24 -"Hikma’s H2 23 results exceeded the street’s expectations, with Generics being the lead performer. Even the 2024 guidance was largely in line with the consensus estimates. The results were cheered by ..."
Pages
53
Language
English
Published on
22/02/24
You may also be interested by these reports :
19/04/25
Despite factoring in some margin pressure in the forecasted years, we have raised our out-year growth estimates for sales and EBITDA to 3.5% (vs. 2% ...
17/04/25
Oral, small molecule GLP-1 candidate Orforglipron shows first phase 3 results – Our take
16/04/25
Ipsen’s Q1 sales aligned with market expectations, showing healthy growth across all segments. The 2025 guidance was reaffirmed. Despite these ...
16/04/25
While Virbac’s Q1 sales slightly missed the street’s estimates, decent growth in both its segments places the firm in a position to meet its ...